Back to Search
Start Over
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
- Source :
-
European journal of haematology [Eur J Haematol] 2004 Apr; Vol. 72 (4), pp. 302-3. - Publication Year :
- 2004
- Subjects :
- Adult
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Asparaginase administration & dosage
Benzamides
Doxorubicin administration & dosage
Fusion Proteins, bcr-abl antagonists & inhibitors
Humans
Imatinib Mesylate
Male
Neoplasm Proteins antagonists & inhibitors
Neoplasm Recurrence, Local
Piperazines therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Prednisone administration & dosage
Pyrimidines therapeutic use
Remission Induction
Stem Cell Transplantation
Transplantation, Homologous
Vincristine administration & dosage
Drug Resistance, Neoplasm
Piperazines administration & dosage
Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Pyrimidines administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 0902-4441
- Volume :
- 72
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- European journal of haematology
- Publication Type :
- Report
- Accession number :
- 15089772
- Full Text :
- https://doi.org/10.1111/j.1600-0609.2004.00212.x